CION Ameerpet
A relapse is not the end of treatment options — it is the start of a different plan. The single most useful number is the gap between your last platinum dose and the relapse, because that gap, more than anything else, decides what is likely to work next.
Most people reading about ovarian cancer recurrence are at one of three moments: waiting on a CA-125 result, holding a scan report that mentions a new nodule, or in remission and quietly trying to work out the odds. The second diagnosis lands differently from the first. The first came out of nowhere. This one arrives after you have already done the hard part once.
The mechanism is not mysterious. First-line treatment removes the disease that can be seen at surgery and treats what chemotherapy can reach. Ovarian cancer, though, spreads by shedding cells across the peritoneal surfaces of the abdomen — a wide, folded, sticky surface with a great many places for a microscopic deposit to sit out a course of chemotherapy. How ovarian cancer spreads explains why that pattern makes complete clearance so difficult, and why relapse is common in advanced disease however well the first treatment went.
So a relapse is not evidence that something was missed or that you did anything wrong. It is the expected behaviour of a disease that was already widespread when it was found. What has changed over the last two decades is the framing: recurrent ovarian cancer is now managed as a long-running, relapsing illness treated in successive lines, with periods off treatment in between, rather than as a single event with one shot at it.
Remission means no detectable disease — not proof that none survives. That gap is why surveillance exists. What remission actually means is worth reading before the first follow-up appointment.
Ovarian cancer seeds across the abdominal lining rather than travelling mainly through the bloodstream. Deposits can be millimetres across and scattered over a very large surface.
The next line is not a repeat of the last one. It is chosen from the interval since platinum, your tumour biology, what you tolerated before, and which side effects you are still carrying.
The words platinum-sensitive and platinum-resistant come from a six-month cut-off that was originally a research convention, not a biological boundary. The Gynecologic Cancer InterGroup, at its Fifth Ovarian Cancer Consensus Conference, concluded that this binary should no longer be the sole basis for choosing treatment at relapse, and recommended describing the treatment-free interval as a continuum, weighed alongside histology, previous response, symptoms and residual toxicity. In other words: the label on your file is shorthand for a conversation, and a relapse at five months and one at seven months are not two different diseases. Source: Wilson MK et al., Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup, Annals of Oncology (2017); NCCN Ovarian Cancer guidelines.
Relapse announces itself in four or five recognisable ways. Which one applies to you matters, because a rising blood test with no symptoms and a scan showing bowel involvement lead to very different conversations.
For women whose CA-125 was raised at diagnosis, a confirmed rise during follow-up is frequently the first signal, and it can precede symptoms or scan changes by several months. One rise is not enough — the marker moves for benign reasons too, and the trend across repeated tests is what carries the information. Rising CA-125 after treatment goes through how to read that trend without reading disaster into a single number.
The uncomfortable part is what follows. The MRC OV05 / EORTC 55955 trial, reported by Rustin and colleagues in The Lancet in 2010, randomised women with a rising CA-125 and no symptoms either to start chemotherapy immediately or to wait until symptoms or signs appeared. Starting early did not improve overall survival, and it meant living with the side effects of chemotherapy for longer. That result is why an experienced team may watch a rising marker rather than treat it, and why that decision is a considered one rather than neglect.
Bloating that will not settle, a waistband that is genuinely tighter, pelvic or abdominal pain, a change in bowel habit, or fatigue that is out of proportion to what you are doing. Most women who have been through this recognise the feeling before any test confirms it, and that instinct is worth acting on rather than talking yourself out of.
Report symptoms between appointments instead of saving them for the next scheduled visit. Follow-up and surveillance after treatment sets out what the schedule is actually for — it is a safety net, not a rule that symptoms have to wait their turn.
CT of the chest, abdomen and pelvis is the standard test for mapping a suspected relapse: where it is, how many sites are involved, whether there is free fluid, and whether the bowel or the ureters are being pressed on. That map is what decides whether the next step is chemotherapy alone or whether surgery is even worth discussing.
PET-CT is used selectively, mostly where CT is equivocal or where confirming that disease is confined to one or two sites would change the plan. At CION, PET-CT is arranged with specialist partner imaging centres rather than performed in-house, and may be billed there.
An abdominal and pelvic examination still finds things that scans schedule for next month: a pelvic mass, a nodule at the vault, a firm lymph node above the collarbone or in the groin, or the shifting dullness of free fluid. It costs nothing and takes two minutes, which is why it belongs at every follow-up visit rather than being replaced by a blood test.
This is also the point at which many women first say out loud that something has felt wrong for weeks. The history and the examination together usually decide how urgently imaging is needed.
A biopsy is not always needed. Where the previous diagnosis is clear and the imaging is characteristic, treatment can proceed without one. It becomes worthwhile when the picture is ambiguous, when a second, unrelated cancer is possible, or when tissue would allow biology to be tested that was never tested the first time.
That second reason matters more than it used to. BRCA status and homologous recombination deficiency directly influence which maintenance options are open to you at relapse. If those tests were never done, a recurrence is a good moment to correct that — genetic counselling and BRCA and HRD testing are delivered in-house at CION.
The interval is counted from your last dose of platinum chemotherapy to the relapse, not from diagnosis and not from surgery. Get that date from your discharge summary before your next appointment — it is the number the whole conversation turns on. The platinum-free interval explained covers how it is counted in detail.
| Term you may hear | Time from the last platinum dose | What it usually signals for the next plan |
|---|---|---|
| Platinum-refractory | Disease progresses during platinum chemotherapy, or within about four weeks of the last dose | Platinum is not controlling this tumour. The next line is chosen from non-platinum options, clinical trials are worth asking about early, and symptom control is planned alongside treatment rather than after it. |
| Platinum-resistant | Relapse less than six months after the last platinum dose | Repeating platinum is unlikely to help much. The usual route is a single-agent non-platinum chemotherapy, sometimes with anti-angiogenic therapy, with quality of life weighed as heavily as response. |
| Partially platinum-sensitive | Relapse between six and twelve months | A genuine grey zone. Platinum may still work, and the decision weighs how well you tolerated it before, any lingering neuropathy or hearing change, and what your BRCA and HRD results open up afterwards. |
| Platinum-sensitive | Relapse more than twelve months after the last platinum dose | Platinum-based combination chemotherapy is usually worth repeating, often followed by maintenance therapy. This is also the group in which surgery for the recurrence is sometimes discussed at selected centres. |
| Treatment-free interval | The wider term now preferred, covering time off any treatment | Used because maintenance therapy blurs the old counting. If you were on maintenance after chemotherapy, ask your team explicitly which interval they are using and from which date. |
*These cut-offs are conventions carried over from clinical trials, not lines drawn in biology. A relapse at five months and one at seven months are far more alike than the labels suggest, which is exactly why the Gynecologic Cancer InterGroup moved away from treating the six-month mark as a switch. Ask which category your team is using and, more usefully, why.
None of these means the cancer has returned. Each is a reason to telephone your oncology team the same day or the next, rather than waiting for a scheduled scan. Between appointments, symptoms are information — not an imposition.
Colicky abdominal pain with vomiting, or no wind or stool passed for a day or more, can mean bowel obstruction. This is a same-day call, not a wait-and-see.
A girth that is visibly increasing over days to weeks, or clothes that stopped fitting this month, suggests fluid collecting. Drainage can relieve it quickly once it is recognised.
Pain that keeps climbing the ladder of painkillers is a change worth reporting in its own right, whatever the cause turns out to be.
Breathlessness lying flat, or on ordinary exertion, may mean fluid in the abdomen pushing up, fluid around the lung, or a clot. All three are treatable and all three want assessing promptly.
Clots are more common in ovarian cancer than in most cancers. A single swollen, tender calf or thigh needs same-day assessment rather than an appointment next week.
New vaginal bleeding, or blood in urine or stool, is not a symptom to file for the next review. It has several possible causes, and each one is easier to deal with early.
If you are between scans and something has changed, say so. Nobody on an oncology team considers a phone call about a new symptom a nuisance — the calls that cause difficulty are the ones that come three weeks late. See follow-up and surveillance for what your schedule is and is not designed to catch.
Bring your discharge summary, chemotherapy dates, CA-125 trend and latest scan. In 45 minutes a specialist can tell you which interval category you fall into, what that opens up, and what it rules out.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
The first consultation is free and there is no referral needed. If your current plan is the right one, we will say so plainly.
A relapse workup is usually shorter than the first diagnosis, because most of the groundwork exists already. What it must not be is rushed — the decisions made here shape the next year or more.
Bring the operation note, the histopathology report, the chemotherapy record with dates, every CA-125 value you have, and the most recent scan on disc. The single most important item is the date of your last platinum dose. Without it, the interval that decides everything else is guesswork.
A full abdominal and pelvic examination, blood counts, kidney and liver function, and CA-125 read as a trend against your own previous values rather than against a population range. Where the marker was never raised at diagnosis, it is not a useful monitor for you and imaging carries more weight.
CT of the chest, abdomen and pelvis maps the relapse. MRI adds detail in the pelvis where surgery is being considered. PET-CT is used selectively, and is arranged with specialist partner imaging centres where it is needed. The question is always concrete: how many sites, where, and is anything threatening the bowel or the kidneys.
BRCA testing (germline and, where indicated, tumour) and HRD testing directly influence which maintenance options exist at relapse. Both, along with genetic counselling for you and for family members who may want testing, are delivered in-house at CION. A relapse is a reasonable moment to close that gap if it was never filled.
Medical oncology, radiology and pathology review the case together. Two questions are answered here: which systemic treatment fits the interval and the biology, and whether this is one of the minority of relapses in which surgery is worth discussing. Where surgery is on the table, it is coordinated with specialist gynaecologic-oncology surgeons at partner centres and may be billed there — CION does not perform it in-house.
Chemotherapy and maintenance therapy are delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, so cycles and follow-up need not mean repeat journeys to one city hospital. Response is assessed after a defined number of cycles rather than continued on faith.
A second opinion at relapse is not disloyalty to your first team, and it is rarely wasted. The choices at this point genuinely diverge — whether to treat a rising marker now or watch it, whether platinum is worth repeating, whether surgery has any role, whether maintenance is open to you — and reasonable specialists weigh them differently. It is worth hearing the reasoning twice.
The first consultation at CION is free and runs to about 45 minutes: long enough to go through the operation note, the chemotherapy dates, the CA-125 trend and the scans properly, rather than glancing at a summary. Cases are reviewed at a tumour board rather than decided by one clinician, and you will be told plainly where the evidence is thin and the decision is a judgement call.
What CION delivers in-house is medical oncology: chemotherapy, maintenance therapy, genetic counselling, BRCA and HRD testing, nutrition support and survivorship follow-up, across 35+ centres. Surgery for a recurrence, HIPEC, intraperitoneal chemotherapy and PET-CT are coordinated with specialist gynaecologic-oncology partner centres and may be billed there. We would rather be straightforward about that division now than have you discover it halfway through a plan.
Long enough to work through the full record and establish which interval category you are actually in — a point that is often assumed rather than checked.
Medical oncology, radiology and pathology review the case together, including whether surgery for the recurrence is worth raising with a partner centre.
BRCA and HRD testing with genetic counselling, in-house. Where these were never done at first diagnosis, they can change what maintenance is available now.
Chemotherapy and maintenance across 35+ centres in Telangana and Andhra Pradesh, so a long treatment course does not become a travel problem as well.
Almost everyone looks up survival figures after a relapse, and almost everyone is misled by them. Published survival for recurrent ovarian cancer is drawn from patients treated years ago, averaged across every stage, subtype and interval category, and mixed together with people whose first surgery cleared everything visible and people whose surgery did not. Maintenance therapy and better testing have changed the picture since much of that data was collected. A single number pulled from that mixture cannot describe your situation, and it will usually understate it.
The more useful questions are answerable: which interval category you fall into, what your BRCA and HRD results are, how many sites are involved, and how well you tolerated treatment last time. Ovarian cancer survival by stage explains what the published figures are actually measuring, and living with advanced ovarian cancer covers what long-term management looks like when the aim is control rather than cure.
CION publishes its own one-year survival next to the national figure so the comparison is visible rather than implied. For ovarian cancer, 81.0% of CION patients are alive at one year, against a national figure of 73.7%. That is a one-year figure across the whole treated population — not a cure rate, and not a prediction for any individual.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population.
The comparable national figure for ovarian cancer. *One-year survival; national registry data.
They are historical, averaged across intervals and subtypes, and collected before current maintenance options existed. They describe a group you may not resemble.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals — discuss your own outlook with your treating oncologist, who can see your interval, your biology and your scans.
No, but recurrence is common when the disease was advanced at diagnosis. Cancers found at an early stage and completely removed have a much lower chance of returning, and many women treated at that point never see it again. In advanced high-grade disease, relapse is the more likely course, which is why surveillance exists at all. The important qualifier is that a recurrence is not the same event as the original diagnosis. There are several lines of treatment available, periods off treatment in between, and maintenance options that did not exist a decade ago. Recurrent ovarian cancer is managed as a long-running illness rather than a single crisis.
They describe the gap between your last dose of platinum chemotherapy and the relapse. Progression during platinum or within about four weeks of the last dose is called platinum-refractory. A relapse within six months is called platinum-resistant. Between six and twelve months is partially platinum-sensitive, and beyond twelve months is platinum-sensitive. The longer the interval, the more likely platinum-based chemotherapy is to work again. These cut-offs came from clinical trials rather than from biology, and international consensus now treats the interval as a continuum weighed alongside your tumour biology, how you tolerated treatment before, and what side effects you are still carrying.
Not automatically, and this surprises people. A large randomised trial, MRC OV05 and EORTC 55955, compared starting chemotherapy as soon as CA-125 rose against waiting until symptoms or clinical signs appeared. Starting early did not improve how long women lived, and it meant months of additional chemotherapy side effects. So a specialist may confirm the trend, arrange a scan, and then watch rather than treat. That is a considered decision, not neglect. It also is not a universal rule: if the scan shows disease threatening the bowel or the kidneys, or symptoms are developing, the calculation changes. Ask your team which situation applies to you.
Usually through one of four routes. A rising CA-125 on routine follow-up is often the earliest signal for women whose marker was raised at diagnosis. Symptoms returning is the next most common: bloating, a tighter waistband, pelvic or abdominal pain, a change in bowel habit or disproportionate fatigue. Sometimes a scan finds it before anything is felt. Sometimes an examination finds a mass or a node. Many women say they knew before any test confirmed it. If something has changed, telephone your team rather than waiting for the next scheduled appointment. Reporting a symptom three weeks earlier occasionally changes what can be offered.
Sometimes, but it is offered to a minority rather than routinely. Surgery for a recurrence is generally considered where the relapse came a long time after platinum chemotherapy, where disease is limited to a small number of sites that could all be removed, where there is no significant ascites, and where you are fit enough to recover well. Outside that group, chemotherapy is the better route and an operation adds risk without adding benefit. At CION this decision is taken at a tumour board, and any surgery is coordinated with specialist gynaecologic-oncology surgeons at partner centres and may be billed there rather than performed in-house.
For most women with a relapse of advanced disease, the realistic aim is control: shrinking the disease, relieving symptoms, and extending good-quality time, with treatment given in lines and breaks in between. Saying that plainly is fairer than implying otherwise. There are exceptions, particularly where a single late relapse can be completely removed surgically, and treatment intent should be discussed openly rather than assumed by either side. Control is not a small thing. Women live for years with recurrent ovarian cancer, on and off treatment, and the goal of each decision is to protect that time rather than to spend it on treatment with little to offer.
It is designed to delay a relapse rather than to prevent one outright. Maintenance is treatment given after chemotherapy has produced a response, to hold that response for as long as possible. PARP-inhibitor-class maintenance is guided by BRCA and HRD status, and the benefit is largest where those results are positive. Anti-angiogenic maintenance is used in other situations. Neither guarantees the cancer will not return, and it is fair to ask your oncologist what the realistic gain is in your case before you commit to months of tablets. If BRCA and HRD testing was never done, ask for it, because it decides what is available.
The first consultation is free and runs to about 45 minutes, which is enough time to go through your operation note, chemotherapy dates, CA-125 trend and scans properly. CION delivers medical oncology in-house: chemotherapy, maintenance therapy, genetic counselling, BRCA and HRD testing, nutrition support and follow-up, across more than 35 centres in Telangana and Andhra Pradesh. Surgery for a recurrence, HIPEC, intraperitoneal chemotherapy and PET-CT are coordinated with specialist gynaecologic-oncology partner centres and may be billed there. Every relapse is reviewed at a tumour board rather than decided by one clinician, and you are told where the decision is a judgement call.